IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Transcode Therapeutics Inc (RNAZ)

CUSIP: 89357L501 | NYSE | Healthcare · Biotechnology | Micro Cap | 19 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13D/ADefj, LLC14,134,48183.9%UnchangedAug 3, 2026No 13F filer matched
13GUnleash Immuno Oncolytics, Inc.300,0009.9%New 5%+ stakeJul 23, 2026

Institutional Holders — Q3 2026

SBI Securities Co., Ltd.12
0.0% of portfolio›$20
IFP Advisors, Inc8
0.0% of portfolio›$13
StyleTurnoverLocationFiled
SBI Securities Co., Ltd.
12$200.0%GrowthLowTokyo, Mexico2026-10-22
IFP Advisors, Inc
8$130.0%CoreLowTampa, FL2026-10-16
No 13F filer matched
13GElena Rosa Braci186,2366.2%New 5%+ stakeJul 23, 2026No 13F filer matched
13GDaniel Eduardo Katzman155,6115.2%New 5%+ stakeJul 23, 2026No 13F filer matched
13D/ADefj, LLC14,134,481
83.9% of class · Aug 3, 2026Unchanged
No 13F filer matched
13GUnleash Immuno Oncolytics, Inc.300,000
9.9% of class · Jul 23, 2026New 5%+ stake
No 13F filer matched
13GElena Rosa Braci186,236
6.2% of class · Jul 23, 2026New 5%+ stake
No 13F filer matched
13GDaniel Eduardo Katzman155,611
5.2% of class · Jul 23, 2026New 5%+ stake
No 13F filer matched